Leadership & Members


David W. Speicher, Ph.D.

Caspar Wistar Professor in Computational and Systems Biology

Professor and Program Co-leader, Molecular and Cellular Oncogenesis Program

Director, The Wistar Institute Center for Systems and Computational Biology
Scientific Director, Proteomics and Metabolomics Facility

David Speicher has been a member of The Wistar Institute since 1986. He received his Ph.D. in Biochemistry at the Pennsylvania State University and his post-doctoral training at Yale University. Dr. Speicher is the author of a textbook on proteomics and is an editor or serves on the editorial board of four major scientific journals. The Speicher laboratory is contributing significantly to the development of the new discipline of proteomics, the systematic study of the full set of proteins produced by a given cell or tissue type. Through a better understanding of proteomics, the Speicher laboratory looks to develop new biological markers for disease and new targets for future drugs.

Research interests include:

  • Proteomics and systems biology analysis of human cancer metastasis and drug resistance.
  • Discovery and validation of prognostic and pharmacokinetic biomarkers of cancers.
  • Discovery and validation of prognostic biomarkers of ectopic pregnancy.
  • Macromolecular interaction mechanisms in complex protein systems.
  • Structure, function, assembly, and regulation of membrane skeletal proteins.


Louise C. Showe, Ph.D.

Professor, Molecular and Cellular Oncogenesis Program
Scientific Director, Genomics Facility
Scientific Director, Bioinformatics Facility
Associate Director, Center for Systems and Computational Biology

Louise Showe received her Ph.D. in Biology from the University of Pennsylvania and did her post-doctoral studies at the Biozentrum der Universitat, Basel, Switzerland. She is a professor and member of the Immunology and Molecular Oncogenesis programs at The Wistar Institute, and Wistar Professor of Dermatology at the University of Pennsylvania. She is also a member of the Executive Committee for the Greater Philadelphia Bioinformatics Alliance and past co-chair for research for the PA Cancer Control Consortium.

Her present research interests have focused on using functional genomics approaches to understanding disease processes with an emphasis on the immune system and cancer. Dr. Showe was awarded one of the first 10 National Cancer Institute’s Directors Challenge grants to develop new molecular criteria for the classification of cancers. She established the first functioning genomics facility in the Philadelphia region and has served as its scientific director since 1999. Her laboratory has actively contributed to the development of bioinformatics at Wistar, focusing on microarray analysis and the development of algorithms for understanding the biology of micro-RNAs, which are short strands of RNA that have been found to have a functional effect in changing how genes are read or “expressed.” 

Research interests include:

  • Identifying patterns of gene and microRNA expression in the development of signatures for diagnosis, prognosis, and response to therapy in non-small cell lung cancer, T cell lymphoma, and HIV.
  • Understanding the immune response to cancer and auto immune disorders.
  • The aging immune response in cancer and vaccine development.


Qihong Huang, M.D., Ph.D.

Ph.D., Assistant Professor, Molecular and Cellular Oncogenesis Program

Research interests include:

  • Functional genomics analysis of tumor development and metastasis.
  • Discovery and functional analysis of non-coding RNAs in tumor progression and metastasis.
  • Discovery of small molecule modulators of microRNAs.

Ken-ichi Noma, Ph.D.

Assistant Professor, Gene Expression and Regulation Program

Research interests include:

  • Modeling the three-dimensional structure of the fission yeast genome.
  • Modeling the three-dimensional structure of the human genome.

Qin Liu, M.D., Ph.D.

Associate Professor. Molecular and Cellular Oncogensis Program

Research interests include:

  • Application of biostatistics in breast and ovarian cancer.